Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia

Am J Gastroenterol. 2011 Dec;106(12):2204-6. doi: 10.1038/ajg.2011.287.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / adverse effects
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Bevacizumab
  • Endoscopy, Gastrointestinal
  • Epistaxis / etiology
  • Epistaxis / prevention & control*
  • Female
  • Gastrointestinal Hemorrhage / drug therapy*
  • Gastrointestinal Tract / pathology
  • Humans
  • Iron / administration & dosage
  • Liver / abnormalities
  • Secondary Prevention
  • Telangiectasia, Hereditary Hemorrhagic / drug therapy*
  • Telangiectasia, Hereditary Hemorrhagic / pathology
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Iron